From a clinical perspective, the present findings if further independently replicated, would suggest that IFNL3 variant testing (either alone or as part of a polygenic risk score) and subsequent risk stratification, could be part of the counselling of patients with SSc who develop PF. The gene discussed is IFNL3; the disease is systemic sclerosis.